Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells

Archives of Pharmacal Research

Volumn 35, Issue 5, 2012, Pages 921-927

  Choi, Min Koo ^a  

^a Dankook University   (South Korea)

Author keywords

CNT1; ENT1; Expression level; Gemcitabine; Inter individual variation; Transport activity

Indexed keywords

ADENOSINE; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CYTARABINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; MESSENGER RNA; NUCLEOSIDE TRANSPORTER; UNCLASSIFIED DRUG; ZALCITABINE;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; CELLS, CULTURED; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE TRANSPORT PROTEINS; NUCLEOSIDE TRANSPORT PROTEINS;

EID: 84862904222     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0518-8     Document Type: Article

References (25)

1. Achiwa, H., Oguri, T., Sato, S., Maeda, H., Niimi, T., and Ueda, R., Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci., 95, 753-757 (2004).
2. Baldwin, S. A., Beal, P. R., Yao, S. Y., King, A. E., Cass, C. E., and Young, J. D., The equilibrative nucleoside transporter family, SLC29. Pflugers Arch., 447, 735-743 (2004).
3. Bhutia, Y. D., Hung, S. W., Patel, B., Lovin, D., and Govindarajan, R., CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res., 71, 1825-1835 (2011).
4. Burke, T., Lee, S., Ferguson, P. J., and Hammond, J. R., Interaction of 2',2'-difluorodeoxycytidine (gemcitabine) and formycin B with the Na+-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells. J. Pharmacol. Exp. Ther., 286, 1333-1340 (1998).
5. Damaraju, V. L., Damaraju, S., Young, J. D., Baldwin, S. A., Mackey, J., Sawyer, M. B., and Cass, C. E., Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene, 22, 7524-7536 (2003).
6. Evans, W. E. and Relling, M. V., Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491 (1999).
7. Giovannetti, E., Del Tacca, M., Mey, V., Funel, N., Nannizzi, S., Ricci, S., Orlandini, C., Boggi, U., Campani, D., Del Chiaro, M., Iannopollo, M., Bevilacqua, G., Mosca, F., and Danesi, R., Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res., 66, 3928-3935 (2006).
8. Gray, J. H., Mangravite, L. M., Owen, R. P., Urban, T. J., Chan, W., Carlson, E. J., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., and Giacomini, K. M., Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol. Pharmacol., 65, 512-519 (2004).
9. 3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line. J. Pharmacol. Exp. Ther., 288, 1185-1191 (1999).
10. Kiss, A., Farah, K., Kim, J., Garriock, R. J., Drysdale, T. A., and Hammond, J. R., Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitorresistant (mENT2) equilibrative nucleoside transporters from mouse brain. Biochem. J., 352 Pt 2, 363-372 (2000).
11. Kong, W., Engel, K., and Wang, J., Mammalian nucleoside transporters. Curr. Drug Metab., 5, 63-84 (2004).
12. Lane, J., Martin, T. A., Mcguigan, C., Mason, M. D., and Jiang, W. G., The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. J. Exp. Ther. Oncol., 8, 203-210 (2010).
13. Li, R. W., Tse, C. M., Man, R. Y., Vanhoutte, P. M., and Leung, G. P., Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists. Eur. J. Pharmacol., 568, 75-82 (2007).
14. Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., Young, J. D., Belt, J. A., Crawford, C. R., and Cass, C. E., Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res., 58, 4349-4357 (1998).
15. Mata, J. F., Garcia-Manteiga, J. M., Lostao, M. P., Fernandez-Veledo, S., Guillen-Gomez, E., Larrayoz, I. M., Lloberas, J., Casado, F. J., and Pastor-Anglada, M., Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol. Pharmacol., 59, 1542-1548 (2001).
16. Meier, Y., Pauli-Magnus, C., Zanger, U. M., Klein, K., Schaeffeler, E., Nussler, A. K., Nussler, N., Eichelbaum, M., Meier, P. J., and Stieger, B., Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology, 44, 62-74 (2006).
17. Myers, S. N., Goyal, R. K., Roy, J. D., Fairfull, L. D., Wilson, J. W., and Ferrell, R. E., Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics, 16, 315-320 (2006).
18. Naito, T., Tokashiki, S., Mino, Y., Otsuka, A., Ozono, S., Kagawa, Y., and Kawakami, J., Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. Basic Clin. Pharmacol. Toxicol., 106, 310-316 (2010).
19. Smith, K. M., Ng, A. M., Yao, S. Y., Labedz, K. A., Knaus, E. E., Wiebe, L. I., Cass, C. E., Baldwin, S. A., Chen, X. Z., Karpinski, E., and Young, J. D., Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J. Physiol., 558, 807-823 (2004).
20. Ueno, H., Kiyosawa, K., and Kaniwa, N., Pharmacogenomics of gemcitabine: can genetic studies lead to tailormade therapy? Br. J. Cancer, 97, 145-151 (2007).
21. Ulrich, C. M., Robien, K., and Mcleod, H. L., Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer, 3, 912-920 (2003).
22. Valdes, R., Ortega, M. A., Casado, F. J., Felipe, A., Gil, A., Sanchez-Pozo, A., and Pastor-Anglada, M., Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology, 119, 1623-1630 (2000).
23. Weinshilboum, R., Inheritance and drug response. N. Engl. J. Med., 348, 529-537 (2003).
24. Wong, A., Soo, R. A., Yong, W. P., and Innocenti, F., Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev., 41, 77-88 (2009).
25. Zimmerman, E. I., Huang, M., Leisewitz, A. V., Wang, Y., Yang, J., and Graves, L. M., Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells. FEBS Lett., 583, 425-429 (2009).